Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
EBITDA · Q3 FY2026 · quarter ended Sep 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$12.16M, compared with -$78.24M a year earlier. Trailing-twelve-month EBITDA was -$185.11M.
Context
- EBITDA amounted to 133.2% of revenue in FY2025, down 68.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$111.16M (+68.3%) for the fiscal year ending Dec 2026, a step up from the -5.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$12.16M+70.7% QoQ
- Last fiscal yearDec 2025
- -$350.89M-5.9% YoY
- LTMSep 2026
- -$185.11M+47.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +84.5% | +84.4% | -0.0 pp |
| 1 year | -5.9% | +68.3% | +74.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (350.89M) USD
- Year-over-year change
- -5.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (350.89M) | -5.9% |
| FY2024 | 2024-12-31 | (331.4M) | +20.0% |
| FY2023 | 2023-12-31 | (414.39M) | -11.5% |
| FY2022 | 2022-12-31 | (371.77M) | -13.3% |
| FY2021 | 2021-12-31 | (328.27M) | — |
EBITDA vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +47.9% is the 3rd highest of 10, against a peer median of +23.4%.
- EBITDA amounts to 48.8% of revenue for IOVA, versus a peer median of 35.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.22B USD | — | -43.3% | 29.5% | |
| LTM Sep 2026 | $99.55M USD | +154.3% | — | 7.3% | |
| LTM Mar 2026 | $6.24M USD | +2711.1% | — | 1.6% | |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$86.7M USD | +32.0% | — | — | |
| LTM Mar 2026 | -$117.42M USD | +23.4% | — | 1859.1% | |
| LTM Sep 2026 | -$185.11M USD | +47.9% | — | 48.8% | |
| LTM Sep 2026 | -$284.54M USD | -45.7% | — | — | |
| LTM Dec 2025 | -$311.38M USD | -33.2% | — | — | |
| LTM Jun 2026 | -€941.06M EUR | -2167.6% | — | 35.6% | |
| LTM Sep 2026 | -$1.01B USD | -332.3% | — | 550.8% | |
| Peer median (excluding IOVA) | — | +23.4% | -43.3% | 35.6% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| Weighted Avg Shares | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
| Weighted Avg Shares (Diluted) | 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.